Human Anti-HA Recombinant Antibody (HPAB-M0100-YC) (CAT#: HPAB-M0100-YC)

Sautto, Giuseppe A., et al. "A computationally optimized broadly reactive antigen subtype-specific influenza vaccine strategy elicits unique potent broadly neutralizing antibodies against hemagglutinin." The Journal of Immunology 204.2 (2020): 375-385. https://doi.org/10.4049/jimmunol.1900379

This study focuses on the development of a computationally optimized broadly reactive antigen (COBRA) subtype-specific influenza vaccine strategy. The research aimed to generate and evaluate the efficacy of a COBRA-based hemagglutinin (HA) immunogen in eliciting broadly neutralizing antibodies against multiple H1N1 influenza viral strains. Through the immunization of mice with the COBRA HA antigen, the study successfully identified monoclonal antibodies (mAbs) with broad hemagglutination inhibition (HAI) activity, capable of recognizing and neutralizing a diverse array of H1N1 strains, both seasonal and pandemic. The findings demonstrated that the COBRA HA vaccine elicited a robust and wide-ranging immune response, providing insights into the design of a more universally protective influenza vaccine.
Creative Biolabs contributed to this study by providing several key monoclonal antibodies used for binding and functional studies, including HA stem-directed human mAbs CR6261, FI6 (Cat#: HPAB-M0100-YC), and F10. These antibodies were essential in the characterization of the immune response elicited by the COBRA HA vaccine. Specifically, they were used to evaluate the breadth and specificity of the antibody response, helping to identify mAbs with the desired broad reactivity and neutralizing capabilities. The reliable performance of these mAbs ensured accurate and reproducible results, supporting the study's goal of advancing the development of a next-generation influenza vaccine.

Abreu, Rodrigo B., et al. "IgA responses following recurrent influenza virus vaccination." Frontiers in immunology 11 (2020): 528797. https://doi.org/10.3389/fimmu.2020.00902

This study investigates the IgA responses following recurrent influenza virus vaccination. Researchers administered the split inactivated influenza vaccine to young adults (18-34 years old) and elderly (65-85 years old) subjects for three consecutive seasons. They then profiled the serological IgA and IgG responses. The study aimed to understand the correlation between vaccine-induced IgA antibody titers and traditional immunological endpoints. The results showed that both young and elderly subjects developed specific IgA responses to the influenza vaccine, highlighting IgA as an important immune correlate during influenza vaccination.
Creative Biolabs contributed to this study by providing the stem-directed monoclonal antibody CR6261 and FI6 (Cat#: HPAB-M0100-YC). These antibodies were used to validate the correct stem conformation of the chimeric HA protein through enzyme-linked immunosorbent assay (ELISA). The involvement of these antibodies was crucial in ensuring the accuracy and reliability of the HA protein structure, thereby supporting the study's evaluation of the serological IgA response to the influenza vaccine.